Screener
BioMarin Pharmaceuticals BMRN Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| ALDURAZYME | $43.54M-22.9% | $36.74M-25.0% | $49.39M+26.5% | $53.71M-24.4% | $56.44M+46.4% | |
| BRINEURA | $51.37M+5.5% | $47.1M+16.7% | $49.39M+3.5% | $47.95M+29.6% | $48.69M+7.5% | |
| GALAFOLD | $105.75M— | —— | —— | —— | $0— | |
| KUVAN | $24.44M-9.6% | $23.88M-5.0% | $23.34M-17.6% | $24.03M-14.5% | $27.03M-5.3% | |
| NAGLAZYME | $135.26M+5.0% | $130.07M+13.8% | $120.22M+9.3% | $122.03M-7.5% | $128.87M-2.4% | |
| PALYNZIQ | $135.17M+27.6% | $89.56M-4.0% | $125.33M+24.8% | $108.78M+20.0% | $105.94M+20.0% | |
| POMBILITI + OPFOLDA | $30.26M— | —— | —— | —— | $0— | |
| ROCTAVIAN | $11.71M+27.3% | $2.64M-74.9% | $12.75M+20.9% | $3.18M-56.0% | $9.2M+23.8% | |
| Royalty and other revenues | $5.32M-57.2% | $6.13M-41.6% | $15.24M+30.5% | $15.32M+29.0% | $12.43M+25.5% | |
| VIMIZIM | $194.37M-9.8% | $210.2M+11.6% | $205.53M+7.6% | $182.76M+2.6% | $215.42M+21.0% | |
| VOXZOGO | $252.53M+14.1% | $219.88M+2.9% | $273.39M+31.1% | $218.39M+15.1% | $221.39M+20.4% |
FAQ
- How does BioMarin Pharmaceuticals break its business down?
- BioMarin Pharmaceuticals (BMRN) reports total revenues by product across 11 parts — ALDURAZYME, BRINEURA, GALAFOLD, KUVAN and NAGLAZYME. Each is extracted from the segment footnotes and tracked over time.
- Where does BioMarin Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BioMarin Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
